Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Colchicine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 known ✓ | Q9H4B7 | 7/20 | 1.00 |
| ▸ | TUBB4A known ✓ | P04350 | 4/20 | 1.00 |
| ▸ | TUBB known ✓ | P07437 | 4/20 | 1.00 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 4/20 | 1.00 |
| ▸ | TUBA1B known ✓ | P68363 | 4/20 | 1.00 |
| ▸ | TUBA4A known ✓ | P68366 | 4/20 | 1.00 |
| ▸ | TUBB4B known ✓ | P68371 | 4/20 | 1.00 |
| ▸ | TUBB3 known ✓ | Q13509 | 4/20 | 1.00 |
| ▸ | TUBB2A known ✓ | Q13885 | 4/20 | 1.00 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 4/20 | 1.00 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 4/20 | 1.00 |
| ▸ | TUBA1A known ✓ | Q71U36 | 4/20 | 1.00 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 4/20 | 1.00 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 4/20 | 1.00 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | MITF | O75030 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Colchicine SCHEMBL8469 | 1.00 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Colchicine SCHEMBL29374654 | 1.00 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Colchicine SCHEMBL1658120 | 1.00 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Colchicine SCHEMBL29376116 | 1.00 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Colchicine SCHEMBL15521905 | 1.00 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Colchicine SCHEMBL8669234 | 1.00 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Colchicine SCHEMBL2006815 | 0.99 | TUBB1 (0.98) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Colchicine SCHEMBL7617204 | 0.99 | TUBB1 (0.98) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Colchicine SCHEMBL2005815 | 0.99 | TUBB1 (0.98) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Colchicine SCHEMBL28039025 | 0.99 | TUBB1 (0.98) | TUBB1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120134963-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2012-05-31 | — | — | US | claimed |
| US-8067401-B2 | Compounds and compositions for treating infection | INTERNATIONAL PATENT HOLDINGS LLC (KN) | 2011-11-29 | — | — | US | claimed |
| US-20090069277-A1 | Compounds and compositions for treating infection | INTERNATIONAL PATENT HOLDINGS LTD. | 2009-03-12 | — | — | US | claimed |
| EP-1330242-A2 | ANTIPROLIFERATIVE COLCHICINE COMPOSITIONS AND USES THEREOF | Chemgenex Therapeutics Inc. (US) | 2003-07-30 | — | — | EP | claimed |
| US-20020123469-A1 | Antiproliferative colchicine compositions and uses thereof | CHEMGENEX THERAPEUTICS, INC. | 2002-09-05 | — | — | US | claimed |
| WO-2002056872-A2 | ANTIPROLIFERATIVE COLCHICINE COMPOSITIONS AND USES THEREOF | CHEMGENEX THERAPEUTICS, INC. (US) | 2002-07-25 | — | — | WO | claimed |
| US-20240238223-A1 | USE OF METHYLAMINOCOLCHICINE AND SALT THEREOF | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240238223-A1 | USE OF METHYLAMINOCOLCHICINE AND SALT THEREOF | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2024-07-18 | — | — | US | disclosed |
| WO-2024107862-A1 | ORAL DOSAGE FORMS FOR THE TREATMENT OF LIVER DISORDERS AND METHODS OF PREPARING THE SAME | VIKING THERAPEUTICS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240101971-A1 | MICROTUBULE DESTABILIZER ADDITIVES TO INCREASE RECOMBINANT VIRAL VECTOR TITERS | BIOGEN MA INC (US) | 2024-03-28 | — | — | US | disclosed |
| EP-4281550-A1 | MICROTUBULE DESTABILIZER ADDITIVES TO INCREASE RECOMBINANT VIRAL VECTOR TITERS | Biogen MA Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230218644-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY RESPIRATORY SYNDROME-RELATED CORONAVIRUS | EWHA WOMANS UNIVERSITY (KR) | 2023-07-13 | — | — | US | disclosed |
| WO-2023087632-A1 | ANTI-INFLAMMATORY ANALGESIC COMPOUND AND USE THEREOF | 江苏新元素医药科技有限公司 | 2023-05-25 | — | — | WO | disclosed |
| WO-2002056872-A2 | ANTIPROLIFERATIVE COLCHICINE COMPOSITIONS AND USES THEREOF | CHEMGENEX THERAPEUTICS, INC. (US) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002056872-A2 | ANTIPROLIFERATIVE COLCHICINE COMPOSITIONS AND USES THEREOF | CHEMGENEX THERAPEUTICS, INC. (US) | 2002-07-25 | — | — | WO | disclosed |
| US-5622848-A | ADMINISTERING ELECTROLYZED SALINE CONTAINING OZONE AND ACTIVE CHLORINE TO TREAT VIRAL AND/OR BACTERIAL INFECTIONS IN BLOOD | MEDICAL DISCOVERIES, INC. (US) | 1997-04-22 | — | — | US | disclosed |
| EP-0767677-A1 | ELECTRICALLY HYDROLYZED SALINES AS IN VIVO MICROBICIDES FOR THE TREATMENT OF CARDIOMYOPATHY AND MULTIPLE SCLEROSIS | MEDICAL DISCOVERIES, INC. (US) | 1997-04-16 | — | — | EP | disclosed |
| WO-1996002271-A1 | ELECTRICALLY HYDROLYZED SALINES AS IN VIVO MICROBICIDES FOR THE TREATMENT OF CARDIOMYOPATHY AND MULTIPLE SCLEROSIS | MEDICAL DISCOVERIES, INC. (US) | 1996-02-01 | — | — | WO | disclosed |
| US-5334383-A | Electrically hydrolyzed salines as in vivo microbicides for treatment of cardiomyopathy and multiple sclerosis | MEDICAL DISCOVERIES, INC. (US) | 1994-08-02 | — | — | US | disclosed |
| WO-1991002084-A1 | METHOD FOR DETECTION AND TREATMENT OF MULTIPLE DRUG-RESISTANT TUMOR CELLS AND USEFUL COLCHICINE DERIVATIVE PROBES | MICHAEL REESE HOSPITAL AND MEDICAL CENTER (US) | 1991-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134963-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | HAVCR2, MAVS, TSG101 | TUBB1 1967/4885TUBB4A 1709/4885TUBB 2297/4885 |
| US-20230218644-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY RESPIRATORY SYNDROME-RELATED CORONAVIRUS | ACE2, ACE, TMPRSS2 | TUBB1 3769/4885TUBB4A 3766/4885TUBB 4027/4885 |
| US-20090069277-A1 | Compounds and compositions for treating infection | RPN2, LSS, CLIC4 | TUBB1 871/4885TUBB4A 239/4885TUBB 192/4885 |
| US-20240238223-A1 | USE OF METHYLAMINOCOLCHICINE AND SALT THEREOF | BCL2L10, BCL2, BCL2L1 | TUBB1 24/4885TUBB4A 47/4885TUBB 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.